Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (symbol: VIRX) is a precision oncology company dedicated to developing innovative therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus (EBV). The company is pioneering a proprietary viral gene activation therapy aimed at treating serious virus-associated diseases.
Viracta is currently conducting three clinical trials for its combination product candidate, designed as a potential treatment for relapsed/refractory EBV-positive lymphoma. This product candidate integrates nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), with valganciclovir, an FDA-approved antiviral drug used to treat cytomegalovirus (CMV) infections.
The company’s research focuses on advancing its Nana-val (nanatinostat and valganciclovir) therapy through various phases of clinical trials. Recent projects include the Phase 1b/2 study of Nana-val in recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.
Viracta Therapeutics is committed to delivering breakthrough treatments that address the unmet medical needs of patients with virus-associated malignancies. The company continues to establish partnerships and collaborations to enhance its research and development capabilities, ensuring a robust pipeline of innovative therapies.
For the latest updates and further information, please visit www.viracta.com.
Viracta Therapeutics (Nasdaq: VIRX) has initiated a Phase 1b/2 trial targeting EBV-positive recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV-positive solid tumors. The trial will assess the safety and preliminary efficacy of the oral combination of nanatinostat and valganciclovir (Nana-val) alone and with pembrolizumab. The study aims to establish the recommended Phase 2 dose and evaluate overall response rates in up to 60 patients. Viracta's innovative approach shows promise for patients with limited treatment options.
Viracta Therapeutics, a precision oncology firm focusing on virus-associated malignancies, will present at multiple upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available from September 13, 2021. Following this, Viracta will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021, at 4:35 PM ET, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:40 AM ET. Details and webcasts are accessible through their investor relations website.
Viracta Therapeutics (NASDAQ: VIRX) announced the reacquisition of exclusive rights to develop and commercialize its all-oral combination therapy in China from Shenzhen Salubris Pharmaceuticals, following a $4.0 million cash payment. The decision aims to align with Viracta's focus on precision oncology and enhance its global development strategy for EBV-associated malignancies. The combination therapy, featuring nanatinostat and valganciclovir, is under evaluation in pivotal trials for EBV-positive lymphoma and nasopharyngeal carcinoma, with a Phase 1b/2 trial set to begin in late 2021.
Viracta Therapeutics (Nasdaq: VIRX) appointed Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors. Dr. Borellini brings over 25 years of experience in oncology drug development, having previously led successful projects at Acerta Pharma and AstraZeneca. Dr. Barlow, currently CEO of Jane Barlow & Associates, has extensive expertise in clinical strategies and pharmaceutical commercialization. These appointments aim to strengthen Viracta's strategic direction and enhance its clinical programs, particularly in EBV-positive lymphoma, as the company seeks to capitalize on its robust financial position and upcoming trials.
Viracta Therapeutics (Nasdaq: VIRX) reported Q2 2021 financial results, highlighting a cash position of approximately $122.7 million and plans for a pivotal clinical trial (NAVAL-1) for EBV-positive lymphoma, now open for enrollment. The company received FDA clearance for a Phase 1b/2 trial in EBV-positive solid tumors, expanding its potential market. Despite an increased net loss of $9.2 million (or $0.25 per share), Viracta aims to leverage its clinical advancements to support future NDA filings. Major executive appointments were also announced.
Viracta Therapeutics (Nasdaq: VIRX) announced FDA clearance for its Investigational New Drug application to start a Phase 1b/2 trial for patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. This study will evaluate the safety and preliminary efficacy of its all-oral combination therapy, including nanatinostat and valganciclovir, along with the PD-1 inhibitor pembrolizumab. The trial aims to enhance treatment options for patients with poor prognosis in these conditions, with initiation expected in the latter half of 2021.
Viracta Therapeutics (Nasdaq: VIRX) has appointed Ayman El-Guindy, Ph.D., as Chief Scientific Officer, enhancing its leadership at a pivotal moment for the company. Patric Nelson, MBA, has joined as Senior VP of Business Development, and Biljana Nadjsombati, Pharm.D., as VP of Pharmaceutical Development. El-Guindy, an expert in EBV-associated cancers, aims to further clinical programs and pipeline expansion. Inducement grants were approved for new employees, facilitating their stock options with an exercise price of $12.53. Viracta focuses on viral malignancies using its investigational drug, nanatinostat.
Viracta Therapeutics (Nasdaq: VIRX) has been added to the small-cap Russell 2000® Index, the Russell 3000® Index, and the Russell Microcap® Index, effective June 28, 2021. This addition follows the 2021 Russell indexes reconstitution, which ranks the 4,000 largest U.S. stocks by market capitalization as of May 7, 2021. Inclusion in the Russell indexes enhances the company's visibility to institutional investors and is significant given that approximately $10.6 trillion in assets benchmark against these indexes.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced the initiation of NAVAL-1, a global Phase 2 trial for treating relapsed/refractory EBV-positive lymphoma. The trial will evaluate the combination of nanatinostat and valganciclovir in approximately 140 patients across North America, Europe, and Asia-Pacific. With a primary endpoint of objective response rate, NAVAL-1 aims to support new drug applications for various lymphoma subtypes. The initiation of this trial is seen as a significant milestone for the company, addressing a critical unmet medical need in oncology.
Viracta Therapeutics (Nasdaq: VIRX) will host a KOL webinar on May 20, 2021, at 2:00 PM ET. The session will discuss nanatinostat and valganciclovir for treating relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma. Renowned experts Dr. Pierluigi Porcu from Thomas Jefferson University and Dr. Kristen Cunanan from Stanford Medicine will present on the treatment landscape and the NAVAL-1 trial design. Attendees can register for the webinar and access materials on Viracta's website after the event.
FAQ
What is the current stock price of Viracta Therapeutics (VIRX)?
What is the market cap of Viracta Therapeutics (VIRX)?
What does Viracta Therapeutics, Inc. specialize in?
What is nanatinostat?
What is valganciclovir used for?
What are the current projects of Viracta Therapeutics?
What is the Nana-val therapy?
Where can I find more information about Viracta Therapeutics?
Who is the contact person for investor relations at Viracta?
What types of cancers is Viracta targeting?
How does Viracta's viral gene activation therapy work?
What is the significance of the Phase 1b/2 study of Nana-val?
